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Abstract—Interleukin-17 (IL-17) is a proinﬂammatory cytokine produced, although not exclusively,
by T helper 17 recently identiﬁed as a distinct T helper lineage mediating tissue inﬂammation. IL-17
is known to be involved in a number of chronic disorders although the mechanisms regulating its
production in inﬂammatory disease are still unclear. The beneﬁcial properties of the polyphenolic
compound resveratrol including its anti-inﬂammatory, antioxidant, and antitumor effects, its role in
the aging process and in the prevention of heart and neurodegenerative diseases are well-known. In
addition, derivatives of resveratrol, including glucosylated molecules as polydatin have been linked
to similar beneﬁcial effects. We have investigated the effects of resveratrol and polydatin on the in
vitro production of IL-17 in a model of inﬂammation in vitro. The results obtained by activated
human peripheral blood mononuclear cells, stimulated with anti-CD3/anti-CD28 monoclonal anti-
bodies and treated with these polyphenolic compounds at different concentrations show that both
decrease IL-17 production in a concentration-dependent manner. This study conﬁrms the anti-inﬂ-
ammatory activity of resveratrol and its derivatives and suggests a potential clinical relevance in the
therapy of inﬂammatory diseases.
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INTRODUCTION
Basic and clinical research provides evidence that
inﬂammatory mechanisms play a central role in the patho-
genesis and progression of many pathological conditions.
In particular, chronic inﬂammatory diseases are
characterized by chronic or relapsing immune activation,
and there is growing evidence that cytokine deregulation
is responsible for the occurrence of these inﬂammatory
and autoimmune pathologies [1–3]. Moreover, inﬂam-
mation is an important environmental factor that
promotes tumorigenesis and progression of established
cancerous lesions, and recent studies have started to
analyze the mechanisms linking the two pathologies [4].
It is therefore evident that modulation of cytokine
production by T cells can play a fundamental role in
the control of various pathologies, and substances able
to modulate this production could have important
immunopharmacological and therapeutic effects.
The family of CD4+ T cells includes different
subtypes of T-helper (Th) lymphocytes characterized by
speciﬁc cytokine proﬁles: Th1 cells produce interleukin
2 (IL-2), interferon-γ, and tumor necrosis factor (TNF)
and are mainly responsible for cell-mediated immunity,
such as retarded hypersensitivity; Th2 cells produce
other types of interleukins such as IL-4, IL-5, IL-6, IL-9,
IL-10, and IL-13 and are mainly responsible for the
regulation of tumor immunity; T helper 17 (Th17) cells,
produce IL-17 family, IL-22, IL-21, and CCL20 and
have a relevant role in immune response to fungi and
extracellular pathogens and inﬂammatory disorders [5, 6].
Moreover, Th17 cells have been characterized as potent
inducers of tissue inﬂammation in several autoimmune
diseases, such as inﬂammatory bowel disease, psoriasis,
multiple sclerosis, systemic lupus erythematosus, rheu-
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matoid arthritis, and Bechet’s disease through the activa-
tion of a wide range of inﬂammatory mediators. The
production of IL-17 indeed induces the secretion of
chemokines and other cytokines, such as IL-6, IL-8,
PGE2, MCP-1, or G-CSF from many kinds of adherent
cells like ﬁbroblasts, keratinocytes, epithelial, and endo-
thelial cells [7, 8]. Moreover, the Th17 response has been
recently implicated in several models of infection [9].
Evidence from human diseases suggests that, like
Th1 and Th2 cells, the in vivo development of Th17 cells
from naïve T cells is dependent on antigen presentation by
professional antigen presenting cells, co-stimulatory stim-
ulation, and a speciﬁc cytokine milieu [10]. In addition, the
differentiation factors responsible for their generation have
revealed an interesting reciprocal relationship with regu-
latory T (Treg) cells, which prevent tissue inﬂammation and
mediate self-tolerance. Furthermore, cytokines that pro-
mote Th17 differentiation are distinct from those that
promote Th1 and Th2 differentiation. Usually, when the
activity of the effector cells is excessive and not balanced
by regulatory cells of the immune system, there is the
increased risk for development of autoimmune diseases.
Therefore, in many autoimmune diseases, the activity of
Th17 exceeds that of Tregs [11–13].
Interleukin-17 is the founding member of a group of
cytokines called the IL-17 family. The IL-17 family is
comprised of at least six members, including IL-17A, IL-
17B, IL-17C, IL-17D, IL-17E (IL-25), and IL-17F. Proto-
type member of the family has been designated IL-17A.
Currently, in addition to Th17 cell subset, a recent
literature describes other cells producing IL-17 in
response to stress, injury, or pathogens. These innate
immune cells have been identiﬁed as: γδ T cell subset
that has an important role at the level of mucosal barrier;
iNKT cells, which are activated in response to self and
non-self glycolipid antigens presented by the non-
polymorphic MHC class I-like CD1d molecule; and
Paneth cells that are highly specialized epithelial cells
involved in mucosal homeostasis. They reside in diverse
anatomical locations—mainly in the lungs, liver, skin,
gut, and secondary lymphoid organs where they have a
broad range of immune regulatory functions that has yet
to be fully understood [14].
Moreover, IL-17 R mRNA exhibits a broad tissue
distribution and has been detected in all cells and tissues
tested [15]. Functional studies have provided evidence
that IL-17 acts on epithelial cells, endothelial cells,
ﬁbroblasts, synoviocytes, and myeloid cells to induce
secretion of a variety of mediators including IL-8, CXC
ligand (CXCL) 1, CXCL6, IL-6, granulocyte macro-
phage colony-stimulating factor, granulocyte colony-
stimulating factor, TGF-β, TNF-α, and IL-1β [16, 17].
Polyphenols, including anthocyanins, ﬂavonoids,
and stilbenes, constitute one of the most abundant and
ubiquitous group of plant metabolites and are an integral
part of the human diet. They are recognized for their
beneﬁcial implications in human health such as in the
treatment and prevention of cancer and cardiovascular
and neurodegenerative diseases. The wide range of
biological effects exhibited is generally believed to be
the outcome of their powerful antioxidant properties in
vitro, which are described in numerous publications
[18].
Resveratrol (3,4′,5-trihydroxy-trans-stilbene, RES)
is a non-ﬂavonoid polyphenol found in several dietary
sources, such as grape seeds, berries, peanuts, and red
wine.
Resveratrol exists as both the trans- and cis-isomer
with numerous reports suggesting trans-resveratrol to be
the more stable form in nature and the most bioactive
form of this molecule. Trans-resveratrol can be readily
converted to cis-resveratrol when exposed to UV light
and is unstable when exposed to high pH. In addition to
resveratrol isomers, derivatives of resveratrol that
include its glucosylated, prenylated, methylated, and
hydroxylated modiﬁcations have been linked with
beneﬁcial activities [19, 20].
In particular, polydatin, also known as piceid
(resveratrol-3-O-β-mono-D-glucoside, POLY) is a gluco-
side of resveratrol in which the glucoside group bonded
in position C-3 substitutes a hydroxyl group. This
substitution gives rise to conformational changes of the
molecule, resulting in changes in the biological proper-
ties. Piceid is more resistant to enzymatic oxidation than
resveratrol, is soluble in water and unlike resveratrol
which penetrates the cell passively it enters the cell via
an active mechanism using glucose carriers [21]. This
property makes polydatin a molecule endowed with
greater bioavailability respect to resveratrol.
Resveratrol is known to have various beneﬁcial
effects such as anti-cancer, antioxidative, anti-inﬂamma-
tory, and cholesterol-lowering activities besides prophy-
lactic effects on cardiovascular diseases. Resveratrol has
been shown to suppress proliferation of a wide variety of
human tumor cells in vitro which has led to numerous
preclinical animal studies to evaluate its cancer preventive
and therapeutic potential. Moreover, it has been reported
that resveratrol exhibits immunomodulatory properties
showing antioxidant and anti-inﬂammatory activities [19,
22, 23]. In particular, Petro TM in its review [24] point out
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the potential therapeutic use of resveratrol, for autoimmune
disease through the modulation of Th17 and Treg cells.
Similarly to resveratrol, polydatin is able to
scavenge free radicals, inhibit platelet aggregation, and
oxidize LDL [25, 26].
In this work, we evaluated the effects of different
concentrations of RES or POLY on normal human
lymphocytes activated in vitro with an inﬂammatory
stimuli. The anti-inﬂammation outcome of RES and POLY
was investigated and compared by evaluating the releasing
of proinﬂammatory IL-17 cytokine in activated T cells.
The evaluation of the immunomodulating effects of
RES or POLY was performed using PBLs stimulated via
CD3/CD28 molecule activation. This method is cur-
rently used to analyze the production of interleukin Il-17
in patients with inﬂammatory diseases as polymyositis
and dermatomyositis, or Crohn’s disease and ulcerative
colitis [27, 28]. Moreover, this technique, simply and
reproducible, permits easy assess to the individual
responses in the clinic.
MATERIALS AND METHODS
Chemicals
Natural RES and POLY were extracted and kindly
supplied by Dr. Fulvio Mattivi, (Fondazione Edmund
Mach, Istituto Agrario di San Michele all’Adige
(IASMA) Italy). The purity of both compounds tested
by HPLC-MS, UV, and NMR was higher than 99%
(method patented and described in) [29, 30].
RES was dissolved in dimethyl sulfoxide (DMSO,
Sigma Chemical Co., St. Louis, USA) at 100 mM stock
solution, whereas POLY was dissolved in Dulbecco’s
modiﬁed Eagle’s medium (DMEM,GIBCO Laborato-
ries, Grand Island, NY, USA) at 100 mM. All stock
solutions were stored at −80°C and diluted in culture
medium just prior to use.
Isolation and Culture of Human Mononuclear Cells
Buffy coats were obtained from peripheral blood of
healthy donors. Peripheral blood mononuclear cells
(PBMC) were puriﬁed by Ficoll-hypaque gradient
centrifugation (Sigma-Aldrich Corp.). The cells at the
interface were removed, washed three times by centri-
fugation at 400×g for 10 min and ﬁnally resuspended at
the appropriate concentration in RPMI-1640 GLUTA-
MAX (GIBCO) medium supplemented with 1% gluta-
mine, 1% penicillin/streptomycin, and 10% heat-
inactivated (56°C, 30 min) fetal calf serum (Hyclone
Laboratories, Logan, UK), herereafter referred to as
complete medium (CM).
Treatment of PBMC with RES or POLY
and Measurement of Il-17 in Culture Supernatants
Isolated PBMC, suspended at the concentration of
106cells/ml in CM, were treated with 1 μg/ml of anti-
CD3 mAb (Clone HIT3a, PharMingen International) and
incubated at 37°C in 5%CO2 for 3 days. At the end of
incubation, the anti-CD3-stimulated lymphocytes were
washed, resuspended in CM containing 1 μg/ml of anti-
CD28 mAb (clone CD28.2, PharMingen International),
and incubated at 37°C in 5% CO2 for additional 3 days.
Immediately before antibody stimulation PBMC
were treated with graded concentration (0.01, 0.1, 1, 2.5,
5, 10, and 20 μg/ml) of RES or POLY. As control, the
cells were treated with vehicle: DMSO and DMEM,
respectively, for RES and POLY treatments.
Cells were analyzed for their cytokine-producing
capability on day 6 at the end of treatments. Cell
proliferation and viability were determined by the
Trypan blue dye exclusion method by manually count-
ing the cells with a hemocytometer. All experiments
were carried out in triplicate.
Culture supernatants of cells stimulated with anti-
CD3/anti-CD28 monoclonal antibodies and treated with
different concentrations of RES or POLY were collected
for IL-17 detection. The test was carried out by ELISA
quantitative sandwich enzyme immunoassay technique
(ELISA kit Quantikine, h-IL-17 immunoassay, R&D
Systems, Minneapolis, USA). The detection limit of the
assays was approximately 15.0 pg/ml and is speciﬁc for
natural and recombinant human IL-17.
Flow Cytometric Analysis
Cytotoxic effects of RES and POLY treatment were
evaluated by ﬂow cytometric analysis. Stimulated and
unstimulated lymphocytes, treated with RES and POLYat
different concentrations (2,5, 5, 10, and 20 μg/ml) and
control cells grown only in culture medium, were ﬁxed in
70% ethanol, washed in PBS, stained with propidium
iodide (PI) 50 μg/ml and incubated in presence of 100 KU/
ml of RNAse in the dark at room temperature for 30 min.
Cellular ﬂuorescence was measured with a FACscan ﬂow
cytometer (Becton Dickinson, Mountain View, CA, USA)
using an argon ion laser emitting at 488 nm. Ten thousand
events were counted for each sample, and data collection
was gated utilizing forward light scatter and side light
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scatter to exclude cell debris and aggregates. Apoptotic
cells are represented by a broad hypodiploid peak below
the G1 peak (cells with a fractional DNA content) in the
red ﬂuorescence channel. This fraction is representative of
cells with decreased staining for PI as an indicator for DNA
fragmentation associated with apoptotic cell death. All data
were recorded using the CellQuest software (Becton &
Dickinson).
IL-17 mRNA Expression-RT-PCR
Total RNAwas extracted from human mononuclear
cells using the RNeasy mini kit (Qiagen) according to
manufacturer’s instructions. The RNA was extracted
from: (1) non-activated cells, (2) cells stimulated with
anti-CD3/anti-CD28, and (3) cells stimulated with anti-
CD3/anti-CD28 and treated with 20 μg/ml of POLY.
Reverse transcription-PCR was carried out with the PCR
CORE kit (Applied Biosystem, Roche) using random
hexamers and 1 μg total RNA for ﬁrst-strand synthesis.
The cDNA encoding IL-17 was ampliﬁed using the
oligonucleotides IL-17 forward (5′-ATGACTCCTGG-
GAAGACCTCATTG-3′) and IL-17 reverse (5′-
ATGACTCCTGGGAAGACCTCA TTG-3′) by 40 PCR
cycles of 95° for 30 s, 70° for 30 s, and 72° for 30 s. As
control, the constitutive human β2 microglobulin cDNA
was PCR ampliﬁed using the oligonucleotides β2
forward (5′- GAA TTG CTA TGT GTC TGG GT- 3′)
and β2 reverse (5′- CAT CTT CAA ACC TCC ATG
ATG- 3′). The ampliﬁed products were electrophoresed
on 2% agarose gel in 1× TAE (Tris acetate EDTA).
Statistical Analysis
Results are expressed in terms of means (M)±
standard error (SE) of the mean. Statistical signiﬁcance
was determined by Student’s test analysis.
RESULTS
Effect of RES and POLY Treatment on IL-17
Production in Activated PBMC In Vitro
Mononuclear cells isolated from peripheral blood
of human healthy donors were treated with RES or
POLY at different concentrations (0.01, 0.1, 1, 2.5, 5, 10,
and 20 μg/ml) and activated with monoclonal anti-CD3/
anti-CD28 antibodies. After 6 days, cell samples were
evaluated for IL-17 production in culture supernatants
by ELISA immunoassay (Fig. 1).
The results illustrated in Fig. 2 show that, at higher
concentrations, RES and POLY treatments result in a
dose-dependent inhibition of IL-17 production by
stimulated PBMC. The results show that POLY treat-
ment of activated PBMC induce a marked inhibition IL-
17 statistically stronger of the inhibition obtained with
Resveratrol 
Polydatin 
Fig. 1. Chemical structure of Resveratrol and Polydatin.
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Fig. 2. Effect of RES and POLY on IL-17 production by PBMC acti-
vated with anti-CD3/ANTI-CD28 monoclonal antibodies. The results
are expressed as percent inhibition of IL-17 production in samples (-
means of triplicate) treated with different concentrations of RES or
POLY respect to untreated stimulated PBMC. The cytokine production
was detected by ELISA immunoassay.
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RES at the same concentration. In particular, POLY
treatment at 20 μg/ml induces an almost complete
inhibition (98%) whereas RES treatment at 20 μg/ml
shows no more than a 50% of inhibition.
On the other hand, at low concentration (0.01 μg/ml),
only RES induces a signiﬁcant increase of IL-17
produced by stimulated PBMC (Fig. 3a), whereas,
POLY treatment at the same concentrations did not
show any signiﬁcant change, although a slight decrease
of cytokine production can be observed early, starting
from 1 μg/ml (Fig. 3b).
Effect of RES and POLY Treatment on Cytotoxicity
of Activated PBMC
To exclude that, downregulation of IL-17 in culture
supernatants was due to cell cytotoxicity by RES or POLY
treatment, cultured cells were manually counted to
evaluate dead cells by TB exclusion. Data show that cell
counts after stimulation and treatment remain substantially
unaffected respect to control cells (data not shown).
To evaluate whether RES or POLY treatment
induced apoptosis, we tested cultured lymphocytes by
ﬂow cytometry analysis. Brieﬂy, unstimulated or stimu-
lated lymphocytes, treated with 2.5, 5, 10 e 20 μg/ml of
RES or POLY were ﬁxed in acetone/methanol 1:4 in
50% PBS and labeled with PI 1 μg/ml. The results in
Fig. 4 show that RES or POLY treatment does not
induce a proapoptotic effect both in unstimulated or
stimulated cells. Only at 20 μg/ml of POLY treatment a
slight signiﬁcative increase in the number of apoptosis
can be observed, both in activated (5.2%) or unstimu-
lated (5.9%) samples.
Effect of RES or POLY on the Expression of IL-17
mRNA in Anti-CD3/ANTI-CD28 Activated
Lymphocytes
Accordingly with data from inhibition of IL-17
activity, IL-17 expression seems to be inhibited by
POLY at RNA level as well. IL-17 cDNAs were
transcribed and ampliﬁed from differently treated human
mononuclear cells and results from a representative
experiment are shown in Fig. 5. The IL-17 mRNA was
clearly down-regulated in cells treated with POLY vs
cell-activated and not activated, suggesting its possible
regulatory role at transcriptional or post transcriptional
level.
DISCUSSION
IL-17 is a cytokine involved in inﬂammatory
conditions such as autoimmune diseases, psoriasis,
arthritis, and inﬂammatory bowel diseases [10, 11, 13].
The data obtained in this study demonstrate the
immunomodulating effects of RES and POLY in an in
vitro model of inﬂammation. The in vitro production
of IL-17 by activated PBMC treated with RES or
POLY at different concentrations has been evaluated.
The results showed that both RES and POLY decrease
IL-17 production in a concentration-dependent man-
ner. A strong inhibitory activity (approximately100%)
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Fig. 3. Effect of low concentrations of RES or POLY on activated
lymphocytes. The results are expressed in terms of IL-17 production
(picograms per milliliter) in PBMC treated with different low concen-
trations of RES or POLY respect to untreated control. The Il-17 pro-
duction was detected by ELISA immunoassay. In panel a, are showed
the effects of treatment of PBMC with RES at 0.01, 0.1, and 1 μg/ml
concentrations respect to untreated control (only vehicle, DMSO). Bars
represent the SE of the mean.*P<0.01 (Student’st test). In panel b, are
showed the effects of POLY at 0,01 0,1 1 μg/ml concentrations respect
to untreated control (only vehicle, DMEM) Bars represent the SE of
the mean.*P<0.05 (Student’st test).
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was obtained by POLY treatment at the concentration
of 20 μg/ml. RES, at the same concentration, also
induces a signiﬁcant inhibition of IL-17 production,
although the level of inhibition was lower (50%).
These results suggest a more effectiveness of POLY in
inhibiting IL-17 production. It is well known that in
POLY, the hydroxyl group in position C-3 is replaced
by a glucoside group that induce a conformational
changes of the molecule and resulting in changed
biological properties. POLY is more resistant to
enzymatic oxidation than RES, it is soluble in water
and, unlike RES which penetrates the cell passively, it
enters the cell through glucose carriers [21, 25], thus,
allowing maximum absorption and a better bioavail-
ability. To establish whether RES and POLY could be
active at low concentrations as well, we treated
stimulated PBMC with either RES or POLY at 0.01,
0.1, and 1 μg/ml. The results showed that only RES at
0.01 μg/ml increases the IL-17 production. This
ﬁnding is in agreement with our previous studies on
immunomodulating activity of RES describing the
effects on cell function and cytokine production in
three models of in vitro immune response [31]. We
previously demonstrated that in vitro treatment of
immune cells with RES induces a biphasic effect:
immunostimulation at low concentrations and strong
inhibition at higher concentrations, for natural (NK
cell) activity, antigen-speciﬁc immune responses and
cytokine production. Son TG et al. successively
conﬁrmed this biphasic dose–response effect on differ-
ent cells and pointed out the hormetic effect by
several phytochemicals compounds [32].
RES is reported as a potent inducer of apoptosis
[33, 34]. To exclude the possibility that a diminished
amount of IL-17 after RES or POLY treatment was
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Fig. 4. Effect of RES and POLY on apoptosis induction in PBMC in
vitro. Lymphocytes stimulated with antiCD3/antiCD28 mAbs, treated
with RES (a) and POLY (b) at 2.5, 5, 10, or 20 μg/ml for 6 days, ﬁxed
and labeled with propidium iodide. The percentage of DNA loss was
measured by ﬂow cytometry and indicated as the percent of hypo-
diploid nuclei.
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Fig. 5. Effect of poly on IL-17 transcription on treated and not treated
PBMC. RT-PCR from untreated PBMC (lane NA), antiCD3/antiCD28
mAbs stimulated PBMC (lane A), and PBMC stimulated and treated
with POLY at 20 μg/ml (lane P). C negative control.
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related to a reduction of number of viable cells, we
tested the effect of RES or POLY treatment on
apoptosis induction. Flow cytometry analysis evi-
denced that only highest concentration of POLY
induced a modest proapoptotic effect. These results
are also in agreement with data from viable cell
enumeration by TB exclusion (data not shown) and
conﬁrm that activated lymphocytes are more resistant
to apoptotic cell death [35].
To further investigate the effect of POLY at the
highest concentration (20 μg/ml), we studied the IL-17
gene expression at the molecular level in stimulated or
unstimulated lymphocytes in vitro.
Accordingly, with data obtained about the IL-17
inhibition in supernatants, IL-17 expression seems to be
inhibited in POLY-treated PBMC at RNA level. From
preliminary data (Fig. 5), the IL-17 mRNA was clearly
down-regulated in activated cells treated with POLY,
suggesting its possible regulatory role at transcriptional
or post-transcriptional level.
As previously described, uncommitted T helper
cells can be induced to differentiate to speciﬁc lineages
according to the local cytokine milieu, towards Th1,
Th2, Th17, and Treg phenotypes in a mutually exclusive
manner [5–7]. Each phenotype is characterized by
unique signaling pathway and expression of speciﬁc
transcription factors, notably T-bet for Th1, GATA-3 for
Th2, forkhead box P3 (FoxP3) for Tregs and receptor-
related orphan receptor (ROR)alpha and RORgamma for
Th17 cells. [11, 13, 36].
Overexpression of RORγt promotes Th17 differ-
entiation; conversely, RORγt deﬁciency results in
profound Th17 deﬁciency. However, RORγt defect did
not completely abolish Th17 differentiation. Th17 cells
also express another orphan nuclear receptor RORα,
which is induced by TGF-β and IL-6 in a STAT3-
dependent manner. Overexpression of RORα promotes
Th17 differentiation and signiﬁcantly upregulates IL-17
expression. RORα deﬁciency results in reduced IL-17
expression in vitro and in vivo. Furthermore, RORα and
RORγt co-expression synergistically drive greater Th17
differentiation especially under non-favorable conditions
[13, 37, 38].
Signal transducer and activator of transcription 3
(STAT3) acts as an important mediator in multiple
biological processes induced by different cytokines
[39]. RORγt the ﬁrst transcription factor to be
selectively expressed in Th17 cells is regulated by
STAT3 [40]. Overexpression of a hyperactive STAT3
enhanced Th17 differentiation while STAT3 deﬁciency
impairs Th17 differentiation in vitro [38, 39] and in
vivo [41]. STAT3 has been shown to bind to IL-17
gene promoter [42] and appears to control IL-17 gene
expression [43]. The precise biochemical function of
STAT3 is unclear, but it could be supposed that it
affects the regulation of lineage-speciﬁc master tran-
scription factors expression. Moreover, recently, IL-21
was reported to regulate Th17 differentiation, as an
autocrine factor induced by IL-6 [44]. STAT3 is also
needed for IL-6 induction and is required for IL-21-
mediated Th17 differentiation [41].
Resveratrol attenuates the activation of immune
cells and modulates the subsequent synthesis and release
of inﬂammatory mediators through the inhibition of
transcriptional factors such as nuclear factor-kappaB
[45]. Resveratrol has also been shown to control other
various transcription factors as STAT3, HIF-1alpha,
beta-catenin, and PPAR-gamma [46]. Resveratrol could
signiﬁcantly inhibit the JAK1/STAT3 signal transduction
pathway, through down-regulation of pJAK1 and
pSTAT3 expression and reducing the phosphorylation
of JAK1 and STAT3 in a dose- and time-dependent
manner [47].
It is reasonable to hypothesize that both RES and
POLY, reducing the phosphorylation of STAT3, regulate
RORγt, the ﬁrst transcription factor selectively expressed
in Th17 cells, and consequentially induce a reduction of
IL-17 production. Further research is in progress in our
laboratory to investigate this molecular pathway.
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